Spain tests a human vaccine against Covid-19 for the first time. The tests carried out so far show that the vaccine protects almost all the lungs.

The Spanish authorities approved the first clinical trial in a group of 190 Spanish volunteers of an anti-COVID 19 vaccine in phase 2 of the study. Research on the Ad26.COV2-S vaccine is carried out by Janssen, which is owned by Johnson & Johnson. Doctors will apply Ad26.COV2-S to another 400 volunteers in Spain, Germany and Belgium.

Based on tests carried out so far, Ad26.COV2-S generates antibodies, which almost completely protect the lungs from exposure to Sars-Cov-2.

The Spanish Agency for Medicines and Health Products (AEMPS) has approved that tests be carried out on 190 healthy subjects in two hospitals in Madrid and one in the city of Santander. In Spain, two groups of volunteers will be established, depending on their age: 18-55 years and over 65 years.

The Spanish Minister of Health, Salvador Illa, assured that the vaccine meets the necessary safety criteria for its administration to people, and the tests will help determine the doses and the time necessary between them.

Spain announced this week that it will participate in the collective order made by the European Commission for the Astra Zeneca anti-Covid vaccine.

Spanish authorities expect at least 10 million doses of the vaccine developed by scientists at the University of Oxford, and the first doses should be available in early December.